Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform ...

Truist raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $520 from $460 and keeps a Buy rating on the shares. The firm is positive on the launch of Journavx, which is seeing “broad ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched ... Vertex is rated Zacks Rank #3 (Hold). The chart below shows the evolution of the company's forward 12-month consensus EPS ...

Biotechnology company Vertex Pharmaceuticals (VRTX) reported mixed results for the fourth quarter of 2024. While revenue surpassed analyst ...

FDA Approves First Non-Opioid Pain Pill, As Medical Marijuana Remains A Proven Alternative For Relief FDA approves non-opioid pain reliever, suzetrigine, by Vertex Pharmaceuticals to mitigate ...

Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

Barclays analyst Gena Wang maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $467.00.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's ... has resulted in a Zacks Rank #3 (Hold) for Vertex. The chart below shows the evolution of the company's forward 12-month ...

Below is a chart showing VRTX's trailing twelve month trading history, with the $470 strike highlighted in orange: Akamai Technologies Inc (Symbol: AKAM) options are showing a volume of 14,642 ...

Below is a chart showing VRTX's trailing twelve month trading history, with the $450.00 strike highlighted in red: Considering the fact that the $450.00 strike represents an approximate 3% premium ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...